Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma

被引:13
|
作者
De Rosa, Anna [1 ]
Fornili, Marco [2 ]
Maestri Tassoni, Michelangelo [1 ]
Guida, Melania [1 ]
Baglietto, Laura [2 ]
Petrucci, Loredana [1 ]
Chella, Antonio [3 ]
Melfi, Franca [4 ]
Lucchi, Marco [5 ]
Ricciardi, Roberta [1 ,5 ]
机构
[1] Univ Pisa, Neurol Unit, Dept Clin & Expt Med, Via Paradisa 2, I-56124 Pisa, Italy
[2] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[3] Univ Hosp Pisa, Unit Pneumol, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
[4] Univ Pisa, Robot Multispecialty Ctr Surg, Minimally Invas & Robot Thorac Surg, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
[5] Univ Hosp Pisa, Dept Cardiol Thorac & Vasc Med, Pisa, Italy
关键词
Antiacetylcholine receptor antibody; myasthenia gravis; thymoma; thymoma recurrence; THYMECTOMY; THERAPY;
D O I
10.1111/1759-7714.13724
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Thymoma-associated myasthenia gravis (TAMG) is one of the subtypes of myasthenia gravis with autoantibodies against the acetylcholine receptor (AChR-Ab). We analyzed the clinical features of our cohort of TAMG patients and the changes in AChR-Ab titer before and after thymectomy in order to identify factors predicting thymoma relapses. Methods We retrospectively assessed: age of MG onset, MG clinical status according to MGFA (Myasthenia Gravis Foundation of America), epoch of thymectomy, post-thymectomy status, oncological features and surgical approach. AChR-Ab dosages were measured both before and after thymectomy. Linear regression models were applied to identify clinical determinants of AChR-Ab titers and the Cox regression model was fitted to estimate the factors associated with the risk of thymoma recurrence. Results The study sample included 239 MG patients, 27 of whom experienced one or more recurrences (median follow-up time: 4.8 years). The AChR-Ab titers decreased after first thymectomy (P < 0.001); the decrease was more pronounced in female patients (P = 0.05), in patients diagnosed with MG at an older age (P = 0.003), and in those who had lower MG stage before surgery (P = 0.02) or higher Masaoka-Koga stage (P = 0.005). The risk of relapse was closely linked with the age of the patient, the Masaoka-Koga stage and the surgical approach. Conclusions Presurgery levels of AChR-Ab or their change after surgery were not associated with thymoma recurrence. The reduction of AChR-Ab titers after thymectomy confirms an immunological role of thymoma in the pathogenesis of MG. Key points Significant findings of the study: Young MG patients with an advanced Masaoka staging score of the primary tumor who underwent thymectomy with approaches different from sternotomy and VATS should be monitored for high risk of recurrence. What this study adds: No other study has ever investigated the changes in AChR-Ab titers before and after thymectomy in a large cohort of TAMG patients. The reduction of AChR-Ab titers after thymectomy suggests an immunological role of thymoma in the pathogenesis of MG.
引用
收藏
页码:106 / 113
页数:8
相关论文
共 50 条
  • [31] IGG SUBCLASS DISTRIBUTION OF MYASTHENIA-GRAVIS THYMOMA-ASSOCIATED ANTISKELETAL MUSCLE ANTIBODIES
    SMITH, CIE
    AARLI, JA
    HAMMARSTROM, L
    PERSSON, MAA
    [J]. NEUROLOGY, 1984, 34 (08) : 1094 - 1096
  • [32] Clinical features of thymoma with and without myasthenia gravis
    Wang, Yaxuan
    Qi, Guoyan
    Yang, Ying
    Yang, Hongxia
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (07) : 1384 - 1390
  • [33] Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis
    Peng Zhang
    Yuxin Liu
    Si Chen
    Xinyu Zhang
    Yuanguo Wang
    Hui Zhang
    Jian Li
    Zhaoyu Yang
    Kai Xiong
    Shuning Duan
    Zeyang Zhang
    Yan Wang
    Ping Wang
    [J]. Scientific Reports, 14
  • [34] Thymus in thymoma-associated myasthenia gravis - Transplantation of thymoma and extrathymomal thymic tissue into SCID mice
    Sarropoulos, A
    Marx, A
    Hohlfeld, R
    Wekerle, H
    Spuler, S
    [J]. EPITHELIAL TUMORS OF THE THYMUS: PATHOLOGY, BIOLOGY, TREATMENT, 1997, : 127 - 133
  • [35] Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis
    Zhang, Peng
    Liu, Yuxin
    Chen, Si
    Zhang, Xinyu
    Wang, Yuanguo
    Zhang, Hui
    Li, Jian
    Yang, Zhaoyu
    Xiong, Kai
    Duan, Shuning
    Zhang, Zeyang
    Wang, Yan
    Wang, Ping
    [J]. SCIENTIFIC REPORTS, 2024, 14 (01)
  • [36] A Rare Case of Thymoma-Associated Idiopathic Inflammatory Myopathy and Myasthenia Gravis
    Schmoll, Chelsea
    Rodenbeck, Stefanie
    [J]. NEUROLOGY, 2023, 100 (17)
  • [37] Thymoma-associated myasthenia gravis coexisting with myotonic dystrophy: a case report
    Miyawaki, Michiyo
    Jikumaru, Mika
    Kamada, Kosuke
    Daiki, Noda
    Abe, Miyuki
    Anami, Kentaro
    Takeuchi, Hideya
    Osoegawa, Atsushi
    Iwao, Sintaro
    Matsubara, Etsuro
    Sugio, Kenji
    [J]. SURGICAL CASE REPORTS, 2021, 7 (01)
  • [38] MYASTHENIA GRAVIS-ASSOCIATED ANTIBODIES IN ASYMPTOMATIC THYMOMA
    MOORE, HJ
    WOODS, EL
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1985, 89 (02): : 308 - 309
  • [39] Neuromyotonia in thymoma-associated myasthenia gravis: a clinico-serological study
    Gastaldi, M.
    de Rosa, A.
    Maestri, M.
    Zardini, E.
    Scaranzin, S.
    Guida, M.
    Borrelli, P.
    Ferraro, O. E.
    Lampasona, V.
    Furlan, R.
    Irani, S.
    Waters, P.
    Lang, B.
    Marchioni, E.
    Ricciardi, R.
    Franciotta, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 351 - 351
  • [40] Long-term prognosis of patients with thymoma-associated myasthenia gravis
    Schalke, BCG
    Schmitt, I
    Marx, A
    Toyka, K
    MullerHermelink, HK
    [J]. EPITHELIAL TUMORS OF THE THYMUS: PATHOLOGY, BIOLOGY, TREATMENT, 1997, : 329 - 335